• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Effect of PIK3CA mutation to anti-cancer drugs of breast cancer.

Research Project

Project/Area Number 21791266
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeSingle-year Grants
Research Field General surgery
Research Institution国立病院機構四国がんセンター (2011)
Department of Clinical Research, National Hospital Organization Shikoku Cancer Center (2009-2010)

Principal Investigator

HARA Fumikata  国立病院機構四国がんセンター, 臨床研究センター, 医師 (00507717)

Project Period (FY) 2009 – 2011
Project Status Completed (Fiscal Year 2011)
Budget Amount *help
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords乳癌 / 薬剤耐性 / PIK3CA遺伝子変異 / ドセタキセル / タモキシフェン / 癌 / 遺伝子 / 医療福祉 / 臨床 / 薬剤反応性
Research Abstract

PIK3CA mutation plays a critical role in the tumorigenesis and resistance of anti-cancer drugs. We evaluated whether PIK3CA mutation would contribute to resistance of docetaxel or tamoxifen in this study. First, we analyzed association between PIK3CA mutation and efficacy of docetaxel in patients who received neoadjuvant docetaxel chemotherapy, but PIK3CA mutation was not associated with sensitivity to docetaxel. Next, we sought to examine interaction between PIK3CA mutation and breast cancer outcomes in patients who are treated with adjuvant tamoxifen alone. In our homogenous dataset of patients treated with tamoxifen alone, the incidence of PIK3CA mutation was 34.1% as consistent to previous studies. Exon9 PIK3CA mutation had a trend to favorable prognosis, in contrast with Exon20 PIK3CA wild type. These two hot spot sites could be different prognostic factor. This may help stratify patients likely to benefit endocrine therapy alone, but our dataset is too small to conclude. Therefore, further studies are needed to confirm this association.

Report

(4 results)
  • 2011 Annual Research Report   Final Research Report ( PDF )
  • 2010 Annual Research Report
  • 2009 Annual Research Report
  • Research Products

    (5 results)

All 2012 2011 Other

All Presentation (4 results) Remarks (1 results)

  • [Presentation] Breast Cancer with PIK3CA Mutations Associated with a Favorable Prognosis in Patients Treated with Tamoxifen Alone2012

    • Author(s)
      Fumikata Hara, Sachiko Kiyoto, Mina Takahashi, Daisuke Takabatake, Seiki Takashima, Kenjiro Aogi, Shozo Ohsumi
    • Organizer
      8^th European Breast Cancer Conference
    • Place of Presentation
      Vienna, Austria
    • Year and Date
      2012-03-22
    • Related Report
      2011 Final Research Report
  • [Presentation] Breast Cancer with PIK3CA Mutations Associated with a Favorable Prognosis in Patients Treated with Tamoxifen Alone2012

    • Author(s)
      原文堅
    • Organizer
      第8回欧州乳癌カンファレンス
    • Place of Presentation
      オーストリア ウイーン
    • Year and Date
      2012-03-22
    • Related Report
      2011 Annual Research Report
  • [Presentation] ドセタキセル単剤術前化学療法を施行された乳癌患者におけるPIK3CA変異と治療効果の関係2011

    • Author(s)
      原文堅、清藤佐知子、高橋三奈、高畠大典、高嶋成輝、青儀健二郎、大住省三
    • Organizer
      第8回日本乳癌学会中国四国地方会
    • Place of Presentation
      香川県高松市
    • Year and Date
      2011-09-10
    • Related Report
      2011 Final Research Report
  • [Presentation] ドセタキセル単剤術前化学療法を施行された乳癌患者におけるPIK3CA変異と治療効果の関係

    • Author(s)
      原文堅
    • Organizer
      乳癌学会中四国
    • Place of Presentation
      香川県高松市
    • Related Report
      2011 Annual Research Report
  • [Remarks] 特記事項なし

    • Related Report
      2009 Annual Research Report

URL: 

Published: 2009-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi